Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H24N4O3.ClH |
Molecular Weight | 440.923 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CC[C@H](NCCO)C4=CC=C3)C#N
InChI
InChIKey=HAOOCAKHSFYDBU-BDQAORGHSA-N
InChI=1S/C23H24N4O3.ClH/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28;/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3;1H/t20-;/m0./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/26990079
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26990079
Ozanimod (previously known as RPC-1063) is a selective immune-inflammatory modulator of the G protein-coupled receptors sphingosine 1-phosphate 1 and 5, which are part of the sphingosine 1-phosphate (S1P) receptor family. Treatment with S1P receptor modulators interferes with S1P signaling and blocks the response of lymphocytes (a type of white blood cell) to exit signals from the lymph nodes, sequestering them within the nodes. The result is a downward modulation of circulating lymphocytes and anti-inflammatory activity by inhibiting cell migration to sites of inflammation. Ozanimod is currently in phase III clinical trials for the treatment of relapsing multiple sclerosis (RMS) and ulcerative colitis, and also in phase II clinical trials to determine whether it is effective in the treatment of Crohn's disease.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26990079
Curator's Comment: effectively crossing the blood–brain barrier resulting in exposure in the brain
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P21453 Gene ID: 1901.0 Gene Symbol: S1PR1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26990079 |
0.41 nM [EC50] | ||
Target ID: Q9H228 Gene ID: 53637.0 Gene Symbol: S1PR5 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26990079 |
11.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.409 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28398597 |
1.5 mg 1 times / day steady-state, oral dose: 1.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OZANIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.66 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28398597 |
1.5 mg 1 times / day steady-state, oral dose: 1.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OZANIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
21.4 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28398597 |
1.5 mg 1 times / day steady-state, oral dose: 1.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OZANIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
0.5 mg 1 times / day multiple, oral Recommended Dose: 0.5 mg, 1 times / day Route: oral Route: multiple Dose: 0.5 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 467 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 467 Sources: Page: 9 |
Other AEs: Nasopharyngitis, Headache... Other AEs: Nasopharyngitis (9.7%) Sources: Page: 9Headache (6%) Upper respiratory tract infection (6.8%) Alanine aminotransferase increased (2.6%) Back pain (2.2%) Gamma-glutamyltransferase increased (2.2%) Respiratory tract infection viral (2.2%) Urinary tract infection (1.8%) Hypercholesterolaemia (1.3%) Hypertension (2.4%) Pharyngitis (1.3%) Rhinitis (1.8%) Upper abdominal pain (2%) |
1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 448 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 448 Sources: Page: 9 |
Other AEs: Nasopharyngitis, Headache... Other AEs: Nasopharyngitis (6.7%) Sources: Page: 9Headache (7.6%) Upper respiratory tract infection (4%) Alanine aminotransferase increased (4.7%) Back pain (3.8%) Gamma-glutamyltransferase increased (3.3%) Respiratory tract infection viral (3.3%) Urinary tract infection (3.8%) Hypercholesterolaemia (2.5%) Hypertension (1.3%) Pharyngitis (2.5%) Rhinitis (2%) Upper abdominal pain (1.3%) |
0.84 mg 1 times / day multiple, oral Recommended Dose: 0.84 mg, 1 times / day Route: oral Route: multiple Dose: 0.84 mg, 1 times / day Sources: Page: 8 |
unhealthy, mean age 35.4 years n = 882 Health Status: unhealthy Condition: multiple sclerosis Age Group: mean age 35.4 years Sex: M+F Population Size: 882 Sources: Page: 8 |
Other AEs: Upper respiratory infection, Transaminases increased... Other AEs: Upper respiratory infection (26%) Sources: Page: 8Transaminases increased (10%) Orthostatic hypotension (4%) Urinary tract infection (4%) Back pain (4%) Hypertension (4%) Abdominal pain upper (2%) |
0.92 mg 1 times / day multiple, oral Recommended Dose: 0.92 mg, 1 times / day Route: oral Route: multiple Dose: 0.92 mg, 1 times / day Sources: Page: 6 |
unhealthy, mean age 35.4 years n = 882 Health Status: unhealthy Condition: multiple sclerosis Age Group: mean age 35.4 years Sex: M+F Population Size: 882 Sources: Page: 6 |
Disc. AE: Hepatic enzymes increased... AEs leading to discontinuation/dose reduction: Hepatic enzymes increased (1%) Sources: Page: 6 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypercholesterolaemia | 1.3% | 0.5 mg 1 times / day multiple, oral Recommended Dose: 0.5 mg, 1 times / day Route: oral Route: multiple Dose: 0.5 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 467 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 467 Sources: Page: 9 |
Pharyngitis | 1.3% | 0.5 mg 1 times / day multiple, oral Recommended Dose: 0.5 mg, 1 times / day Route: oral Route: multiple Dose: 0.5 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 467 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 467 Sources: Page: 9 |
Rhinitis | 1.8% | 0.5 mg 1 times / day multiple, oral Recommended Dose: 0.5 mg, 1 times / day Route: oral Route: multiple Dose: 0.5 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 467 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 467 Sources: Page: 9 |
Urinary tract infection | 1.8% | 0.5 mg 1 times / day multiple, oral Recommended Dose: 0.5 mg, 1 times / day Route: oral Route: multiple Dose: 0.5 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 467 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 467 Sources: Page: 9 |
Upper abdominal pain | 2% | 0.5 mg 1 times / day multiple, oral Recommended Dose: 0.5 mg, 1 times / day Route: oral Route: multiple Dose: 0.5 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 467 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 467 Sources: Page: 9 |
Back pain | 2.2% | 0.5 mg 1 times / day multiple, oral Recommended Dose: 0.5 mg, 1 times / day Route: oral Route: multiple Dose: 0.5 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 467 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 467 Sources: Page: 9 |
Gamma-glutamyltransferase increased | 2.2% | 0.5 mg 1 times / day multiple, oral Recommended Dose: 0.5 mg, 1 times / day Route: oral Route: multiple Dose: 0.5 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 467 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 467 Sources: Page: 9 |
Respiratory tract infection viral | 2.2% | 0.5 mg 1 times / day multiple, oral Recommended Dose: 0.5 mg, 1 times / day Route: oral Route: multiple Dose: 0.5 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 467 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 467 Sources: Page: 9 |
Hypertension | 2.4% | 0.5 mg 1 times / day multiple, oral Recommended Dose: 0.5 mg, 1 times / day Route: oral Route: multiple Dose: 0.5 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 467 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 467 Sources: Page: 9 |
Alanine aminotransferase increased | 2.6% | 0.5 mg 1 times / day multiple, oral Recommended Dose: 0.5 mg, 1 times / day Route: oral Route: multiple Dose: 0.5 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 467 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 467 Sources: Page: 9 |
Headache | 6% | 0.5 mg 1 times / day multiple, oral Recommended Dose: 0.5 mg, 1 times / day Route: oral Route: multiple Dose: 0.5 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 467 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 467 Sources: Page: 9 |
Upper respiratory tract infection | 6.8% | 0.5 mg 1 times / day multiple, oral Recommended Dose: 0.5 mg, 1 times / day Route: oral Route: multiple Dose: 0.5 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 467 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 467 Sources: Page: 9 |
Nasopharyngitis | 9.7% | 0.5 mg 1 times / day multiple, oral Recommended Dose: 0.5 mg, 1 times / day Route: oral Route: multiple Dose: 0.5 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 467 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 467 Sources: Page: 9 |
Hypertension | 1.3% | 1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 448 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 448 Sources: Page: 9 |
Upper abdominal pain | 1.3% | 1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 448 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 448 Sources: Page: 9 |
Rhinitis | 2% | 1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 448 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 448 Sources: Page: 9 |
Hypercholesterolaemia | 2.5% | 1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 448 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 448 Sources: Page: 9 |
Pharyngitis | 2.5% | 1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 448 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 448 Sources: Page: 9 |
Gamma-glutamyltransferase increased | 3.3% | 1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 448 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 448 Sources: Page: 9 |
Respiratory tract infection viral | 3.3% | 1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 448 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 448 Sources: Page: 9 |
Back pain | 3.8% | 1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 448 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 448 Sources: Page: 9 |
Urinary tract infection | 3.8% | 1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 448 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 448 Sources: Page: 9 |
Upper respiratory tract infection | 4% | 1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 448 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 448 Sources: Page: 9 |
Alanine aminotransferase increased | 4.7% | 1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 448 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 448 Sources: Page: 9 |
Nasopharyngitis | 6.7% | 1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 448 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 448 Sources: Page: 9 |
Headache | 7.6% | 1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: Page: 9 |
unhealthy, 18 - 55 years n = 448 Health Status: unhealthy Condition: multiple sclerosis Age Group: 18 - 55 years Sex: M+F Population Size: 448 Sources: Page: 9 |
Transaminases increased | 10% | 0.84 mg 1 times / day multiple, oral Recommended Dose: 0.84 mg, 1 times / day Route: oral Route: multiple Dose: 0.84 mg, 1 times / day Sources: Page: 8 |
unhealthy, mean age 35.4 years n = 882 Health Status: unhealthy Condition: multiple sclerosis Age Group: mean age 35.4 years Sex: M+F Population Size: 882 Sources: Page: 8 |
Abdominal pain upper | 2% | 0.84 mg 1 times / day multiple, oral Recommended Dose: 0.84 mg, 1 times / day Route: oral Route: multiple Dose: 0.84 mg, 1 times / day Sources: Page: 8 |
unhealthy, mean age 35.4 years n = 882 Health Status: unhealthy Condition: multiple sclerosis Age Group: mean age 35.4 years Sex: M+F Population Size: 882 Sources: Page: 8 |
Upper respiratory infection | 26% | 0.84 mg 1 times / day multiple, oral Recommended Dose: 0.84 mg, 1 times / day Route: oral Route: multiple Dose: 0.84 mg, 1 times / day Sources: Page: 8 |
unhealthy, mean age 35.4 years n = 882 Health Status: unhealthy Condition: multiple sclerosis Age Group: mean age 35.4 years Sex: M+F Population Size: 882 Sources: Page: 8 |
Back pain | 4% | 0.84 mg 1 times / day multiple, oral Recommended Dose: 0.84 mg, 1 times / day Route: oral Route: multiple Dose: 0.84 mg, 1 times / day Sources: Page: 8 |
unhealthy, mean age 35.4 years n = 882 Health Status: unhealthy Condition: multiple sclerosis Age Group: mean age 35.4 years Sex: M+F Population Size: 882 Sources: Page: 8 |
Hypertension | 4% | 0.84 mg 1 times / day multiple, oral Recommended Dose: 0.84 mg, 1 times / day Route: oral Route: multiple Dose: 0.84 mg, 1 times / day Sources: Page: 8 |
unhealthy, mean age 35.4 years n = 882 Health Status: unhealthy Condition: multiple sclerosis Age Group: mean age 35.4 years Sex: M+F Population Size: 882 Sources: Page: 8 |
Orthostatic hypotension | 4% | 0.84 mg 1 times / day multiple, oral Recommended Dose: 0.84 mg, 1 times / day Route: oral Route: multiple Dose: 0.84 mg, 1 times / day Sources: Page: 8 |
unhealthy, mean age 35.4 years n = 882 Health Status: unhealthy Condition: multiple sclerosis Age Group: mean age 35.4 years Sex: M+F Population Size: 882 Sources: Page: 8 |
Urinary tract infection | 4% | 0.84 mg 1 times / day multiple, oral Recommended Dose: 0.84 mg, 1 times / day Route: oral Route: multiple Dose: 0.84 mg, 1 times / day Sources: Page: 8 |
unhealthy, mean age 35.4 years n = 882 Health Status: unhealthy Condition: multiple sclerosis Age Group: mean age 35.4 years Sex: M+F Population Size: 882 Sources: Page: 8 |
Hepatic enzymes increased | 1% Disc. AE |
0.92 mg 1 times / day multiple, oral Recommended Dose: 0.92 mg, 1 times / day Route: oral Route: multiple Dose: 0.92 mg, 1 times / day Sources: Page: 6 |
unhealthy, mean age 35.4 years n = 882 Health Status: unhealthy Condition: multiple sclerosis Age Group: mean age 35.4 years Sex: M+F Population Size: 882 Sources: Page: 6 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209899Orig1s000PharmR.pdf#page=30 Page: 30.0 |
||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209899Orig1s000PharmR.pdf#page=30 Page: 30.0 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02576717
Multiple Sclerosis: 1 mg RPC1063 (Ozanimod) oral capsule daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26990079
Ozanimod (RPC1063) is a specific agonist for sphingosine-1-phosphate receptor subtypes 1 (S1P1) and S1P5 receptors. The EC50 values were 0.16 nM and 0.41 nM for S1P1 receptors in the inhibition of cAMP generation and [35S]-GTPγS binding. The 83% Emax value of ozanimod against S1P5 receptor was 11 nM. RPC1063 demonstrated a dose‐dependent effect on S1P1 receptor re‐expression on the cell surface, with near complete and sustained loss of cell surface receptor expression at concentrations above 10 nM in S1P1 receptor-HEK293T cells after 1 h incubation.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m12197
Created by
admin on Fri Dec 15 19:19:44 GMT 2023 , Edited by admin on Fri Dec 15 19:19:44 GMT 2023
|
PRIMARY | |||
|
91618104
Created by
admin on Fri Dec 15 19:19:44 GMT 2023 , Edited by admin on Fri Dec 15 19:19:44 GMT 2023
|
PRIMARY | |||
|
1618636-37-5
Created by
admin on Fri Dec 15 19:19:44 GMT 2023 , Edited by admin on Fri Dec 15 19:19:44 GMT 2023
|
PRIMARY | |||
|
C166700
Created by
admin on Fri Dec 15 19:19:44 GMT 2023 , Edited by admin on Fri Dec 15 19:19:44 GMT 2023
|
PRIMARY | |||
|
100000182766
Created by
admin on Fri Dec 15 19:19:44 GMT 2023 , Edited by admin on Fri Dec 15 19:19:44 GMT 2023
|
PRIMARY | |||
|
SUB197076
Created by
admin on Fri Dec 15 19:19:44 GMT 2023 , Edited by admin on Fri Dec 15 19:19:44 GMT 2023
|
PRIMARY | |||
|
CHEMBL3707247
Created by
admin on Fri Dec 15 19:19:44 GMT 2023 , Edited by admin on Fri Dec 15 19:19:44 GMT 2023
|
PRIMARY | |||
|
2288235
Created by
admin on Fri Dec 15 19:19:44 GMT 2023 , Edited by admin on Fri Dec 15 19:19:44 GMT 2023
|
PRIMARY | |||
|
DTXSID201026489
Created by
admin on Fri Dec 15 19:19:44 GMT 2023 , Edited by admin on Fri Dec 15 19:19:44 GMT 2023
|
PRIMARY | |||
|
DBSALT002947
Created by
admin on Fri Dec 15 19:19:44 GMT 2023 , Edited by admin on Fri Dec 15 19:19:44 GMT 2023
|
PRIMARY | |||
|
3UPR33JAAM
Created by
admin on Fri Dec 15 19:19:44 GMT 2023 , Edited by admin on Fri Dec 15 19:19:44 GMT 2023
|
PRIMARY | |||
|
CD-22
Created by
admin on Fri Dec 15 19:19:44 GMT 2023 , Edited by admin on Fri Dec 15 19:19:44 GMT 2023
|
PRIMARY | |||
|
3UPR33JAAM
Created by
admin on Fri Dec 15 19:19:44 GMT 2023 , Edited by admin on Fri Dec 15 19:19:44 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD